Cognitive and psychoemotional changes in menopausal transition: The possibility of medical correction

The increasing of older age group in the population determines studying of age related diseases and emergence of new investigations in this area. In Female body, entering the menopausal transition is the start of «aging» of reproductive function and linked with decreasing of sex hormons levels. A direct connection between changes of estrogen, progesterone, androgen ratios and cognitive function of women was revealed. The anatomical localization of sex hormone receptors, the mechanisms of interaction of hormones with these receptors determine the ways of implementing biological effects of steroids on the CNS. Modern theories of «healthy nerve cells» and «eu-estrogenemia» explains the role of additional criteria, such as the absence of neurological diseases history and the duration of hypoestrogenia, to the outcome of menopausal hormone therapy. Additional factors that can affect to MHT action include: the composition of hormone therapy, administration methods, regimens (cyclic, continuous), duration of treatment, history of endocrine diseases, diabetes mellitus, gynecological history (parity, menarche age, COC use), heredity. The sections present the effect of menopausal transition on the development of depression, mood changes, sleep disturbances and mental disabilities. The explanation of negative effects of menopausal hormone therapy to cognitive health is also described by modern point of view. The ambivalent opinions of researchers, the potential of new reading of the results of earlier studies, confirms the necessity of continuing study of this topic.

1. World Health Organization [Internet]. Dementia. 2020. (In Russ.). Доступно по: https://www.who.int/ru/news-room/fact-sheets/detail/dementia. Ссылка активна на 10.01.2023.

2. Beard JR, Officer A, de Carvalho IA, et al. The World report on ageing and health: a policy framework for healthy ageing. Lancet. 2016;387(10033):2145-2154. doi: https://doi.org/10.1016/S0140-6736(15)00516-4

3. Maki PM, Thurston RC. Menopause and brain health: hormonal changes are only part of the story. Front Neurol. 2020;11(6):421-427. doi: https://doi.org/10.3389/fneur.2020.562275

4. Rudnicka E, Napierała P, Podfigurna A, et al. The World Health Organization (WHO) approach to healthy ageing. Maturitas. 2020;139(6):6-11. doi: https://doi.org/10.1016/j.maturitas.2020.05.018

5. Karlamangla AS, Lachman ME, Han W, et al. Evidence for cognitive aging in midlife women: study of women’s health across the nation. PLoS One. 2017;12(1):e0169008. doi: https://doi.org/10.1371/journal.pone.0169008

6. Ashrafian LA, Balan VE, Baranov II, et al. Algorithms for menopausal hormone therapy during the period of peri- and postmenopause. Joint position statement of RSOG RAM, AGE, RAOP experts. Obstetrics and gynecology. 2021;(3):210-221. (In Russ.). doi: https://doi.org/10.18565/aig.2021.3.210-221

7. Radzinskii VE, Khamoshina MB, Raevskaia OA, et al. Ocherki endokrinnoi ginekologii. Moscow: Mediabiuro Status Prezens; 2020. (In Russ.).

8. Gasparyan SA, Drosova LD, Karpov SM, et al. Use of menopausal hormone therapy in the correction of cognitive impairment in menopausal women. Obstetrics and gynecology. 2018;(3):157-162. (In Russ.). doi: https://doi.org/10.18565/aig.2018.12.157-162

9. Dause TJ, Kirby ED. Aging gracefully: social engagement joins exercise and enrichment as a key lifestyle factor in resistance to age-related cognitive decline. Neural Regen Res. 2019;14(1):39-42. doi: https://doi.org/10.4103/1673-5374.243698

10. Gasparyan SA, Drosova LD, Khripunova AA. The effect of low-dose drospirenone and 17β-estradiol for correction of the manifestations of climacteric syndrome in postmenopausal women. Medical Council. 2017;(2):82-86. (In Russ.). doi: https://doi.org/10.21518/2079-701X-2017-2-82-86

11. Gasparyan SA, Vasilenko IA, Papikova KA, et al. Menopause: up the stairs leading down. Medical Council. 2020;(13):76-83. (In Russ.). doi: https://doi.org/10.21518/2079-701X-2020-13-76-83

12. Dubrovina SO. Rational approach to hormonal therapy among women after 40 years. Obstetrics and gynecology. 2019;(7):112-116. (In Russ.). doi: https://doi.org/10.18565/aig.2019.7.112-116

13. Rossiiskoe obshchestvo akusherov-ginekologov. Menopauza i klimaktericheskoe sostoianie u zhenshchiny. Klinicheskie rekomendatsii. Moscow: Rossiiskoe obshchestvo akusherov-ginekologov; 2021. (In Russ).

14. Gava G, Orsili I, Alvisi S, et al. Cognition, mood and sleep in menopausal transition: The role of menopause hormone therapy. Medicina (Kaunas). 2019;55(10):668. doi: https://doi.org/10.3390/medicina55100668

15. Turner RJ, Kerber IJ. A theory of eu-estrogenemia: a unifying concept. Menopause. 2017;24(9):1086-1097. doi: https://doi.org/10.1097/GME.0000000000000895

16. Rentz DM, Weiss BK, Jacobs EG, et al. Sex differences in episodic memory in early midlife: impact of reproductive aging. Menopause. 2017;24(4):400-408. doi: https://doi.org/10.1097/GME.0000000000000771

17. Kuh D, Cooper R, Moore A, et al. Age at menopause and lifetime cognition: Findings from a British birth cohort study. Neurology. 2018;90(19):e1673-e1681. doi: https://doi.org/10.1212/WNL.0000000000005486

18. Greendale GA, Han W, Huang M, et al. Longitudinal assessment of physical activity and cognitive outcomes among women at midlife. JAMA Netw Open. 2021;4(3):e213227. doi: https://doi.org/10.1001/jamanetworkopen.2021.3227

19. Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, et al. Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study. BMJ. 2019;12(6):l665. doi: https://doi.org/10.1136/bmj.l665

20. Imtiaz B, Taipale H, Tanskanen A, et al. Risk of Alzheimer’s disease among users of postmenopausal hormone therapy: A nationwide case-control study. Maturitas. 2017;(98):7-13. doi: https://doi.org/10.1016/j.maturitas.2017.01.002

21. Morgan KN, Derby CA, Gleason CE. Cognitive changes with reproductive aging, perimenopause, and menopause. Obstet Gynecol Clin North Am. 2018;45(4):751-763. doi: https://doi.org/10.1016/j.ogc.2018.07.011

22. Espeland MA, Brinton RD, Hugenschmidt C, et al. WHIMS Study Group. Impact of type 2 diabetes and postmenopausal hormone therapy on incidence of cognitive impairment in older women. Diabetes Care. 2015;38(12):2316-2324. doi: https://doi.org/10.2337/dc15-1385

23. ThyagaRajan S, Hima L, Pratap UP, et al. Estrogen-induced neuroimmunomodulation as facilitator of and barrier to reproductive aging in brain and lymphoid organs. J Chem Neuroanat. 2019;95(6):6-12. doi: https://doi.org/10.1016/j.jchemneu.2018.02.008

24. Engler-Chiurazzi EB, Brown CM, Povroznik JM, Simpkins JW. Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury. Prog Neurobiol. 2017;157(3):188-211. doi: https://doi.org/10.1016/j.pneurobio.2015.12.008

25. Jaff NG, Maki PM. Scientific insights into brain fog during the menopausal transition. Climacteric. 20m21;24(4):317-318. doi: https://doi.org/10.1080/13697137.2021

26. Reuben R, Karkaby L, McNamee C, et al. Menopause and cognitive complaints: are ovarian hormones linked with subjective cognitive decline? Climacteric. 2021;24(4):321-332. doi: https://doi.org/10.1080/13697137.2021.1892627

27. Dotlic J, Radovanovic S, Rancic B, et al. Mental health aspect of quality of life in the menopausal transition. J Psychosom Obstet Gynaecol. 2021;42(1):40-49. doi: https://doi.org/10.1080/0167482X.2020.1734789

28. Morgan KN, Derby CA, Gleason CE. Cognitive Changes with Reproductive Aging, Perimenopause, and Menopause. Obstet Gynecol Clin North Am. 2018;45(4):751-763. doi: https://doi.org/10.1016/j.ogc.2018.07.011

29. Hara Y, Waters EM, McEwen BS, et al. Estrogen effects on cognitive and synaptic health over the lifecourse. Physiol Rev. 2015;95(3):785-807. doi: https://doi.org/10.1152/physrev.00036.2014

30. Gava G, Visconti M, Salvi F, et al. Prevalence and psychopathological determinants of sexual dysfunction and related distress in women with and without multiple sclerosis. J Sex Med. 2019;16(6):833-842. doi: https://doi.org/10.1016/j.jsxm.2019.03.011

31. McCarrey AC, Resnick SM. Postmenopausal hormone therapy and cognition. Horm Behav. 2015;74(6):167-172. doi: https://doi.org/10.1016/j.yhbeh.2015.04.018

32. Denley MCS, Gatford NJF, Sellers KJ, Srivastava DP. Estradiol and the development of the cerebral cortex: An unexpected role? Front Neurosci. 2018;12(6):6-11. doi: https://doi.org/10.3389/fnins.2018.00245

33. Kantarci K, Lowe VJ, Lesnick TG, et al. Early postmenopausal transdermal 17β-estradiol therapy and amyloid-β deposition. J Alzheimers Dis. 2016;53(2):547-556. doi: https://doi.org/10.3233/JAD-160258

34. Kantarci K, Tosakulwong N, Lesnick TG, et al. Effects of hormone therapy on brain structure: A randomized controlled trial. Neurology. 2016;87(9):887-896. doi: https://doi.org/10.1212/WNL.0000000000002970

35. Karim R, Dang H, Henderson VW, et al. Effect of reproductive history and exogenous hormone use on cognitive function in mid- and late life. J Am Geriatr Soc. 2016;64(12):2448-2456. doi: https://doi.org/10.1111/jgs.14658

36. Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: Findings from the randomized, controlled KEEPS–cognitive and affective study. PLOS Med. 2015;12(6):e1001833. doi: https://doi.org/10.1371/journal.pmed.1001833

37. Guérin E, Goldfield G, Prud’homme D. Trajectories of mood and stress and relationships with protective factors during the transition to menopause: results using latent class growth modeling in a Canadian cohort. Arch Womens Ment Health. 2017;20(6):733-745. doi: https://doi.org/10.1007/s00737-017-0755-4

38. Soares CN. Depression and menopause: An update on current knowledge and clinical management for this critical window. Med Clin North Am. 2019;103(4):651-667. doi: https://doi.org/10.1016/j.mcna.2019.03.001

39. Bruyneel M. Sleep disturbances in menopausal women: Aetiology and practical aspects. Maturitas. 2015;81(3):406-409. doi: https://doi.org/10.1016/j.maturitas.2015.04.017

40. Schmidt PJ, Ben Dor R, Martinez PE, et al. Effects of estradiol withdrawal on mood in women with past perimenopausal depression: A randomized clinical trial. JAMA Psychiatry. 2015;72(7):714-726. doi: https://doi.org/10.1001/jamapsychiatry.2015.0111

41. Rubinow DR, Johnson SL, Schmidt PJ, et al. Efficacy of estradiol in perimenopausal depression: so much promise and so few answers. Depress Anxiety. 2015;32(8):539-549. doi: https://doi.org/10.1002/da.22391

42. Wilson L, Pandeya N, Byles J, et al. Hysterectomy and incidence of depressive symptoms in midlife women: the Australian Longitudinal Study on Women’s Health. Epidemiol Psychiatr Sci. 2018;27(4):381-392. doi: https://doi.org/10.1017/S2045796016001220

43. Hickey M, Schoenaker DA, Joffe H, et al. Depressive symptoms across the menopause transition: findings from a large population-based cohort study. Menopause. 2016;23(12):1287- 1293. doi: https://doi.org/10.1097/GME.0000000000000712

44. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, et al. Estradiol variability, stressful life events, and the emergence of depressive symptomatology during the menopausal transition. Menopause. 2016;23(3):257-266. doi: https://doi.org/10.1097/GME.0000000000000528

45. Metcalf CA, Johnson RL, Freeman EW, et al. Influences of the menopause transition and adverse childhood experiences on peripheral basal inflammatory markers. Brain Behav Immun Health. 2021 Jun 1;15:100280. doi: https://doi.org/10.1016/j.bbih.2021.100280

46. Maki PM, Kornstein SG, Joffe H, et al. Board of trustees for the North American Menopause Society (NAMS) and the women and mood disorders task force of the National Network of Depression Centers. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause. 2018;25(10):1069-1085. doi: https://doi.org/10.1097/GME.0000000000001174

47. Green SM, Key BL, McCabe RE. Cognitive-behavioral, behavioral, and mindfulness-based therapies for menopausal depression: a review. Maturitas. 2015;80(1):37-47. doi: https://doi.org/10.1016/j.maturitas.2014.10.004

48. Yureneva SV, Ermakova EI. Evaluation of the effectiveness of alternative treatments for menopausal symptoms in postmenopausal women. Medical Council. 2017;(2):76-80. (In Russ.). doi: https://doi.org/10.21518/2079-701X-2017-2-76-80

49. Jehan S, Masters-Isarilov A, Salifu I, et al. Sleep disorders in postmenopausal women. J Sleep Disord Ther. 2015;4(5):212.

50. Baker FC, de Zambotti M, Colrain IM, Bei B. Sleep problems during the menopausal transition: prevalence, impact, and management challenges. Nat Sci Sleep. 2018;10(6):73-95. doi: https://doi.org/10.2147/NSS.S125807

51. Bruyneel M. Sleep disturbances in menopausal women: Aetiology and practical aspects. Maturitas. 2015;81(3):406-409. doi: https://doi.org/10.1016/j.maturitas.2015.04.017